The therapeutic role of targeting protein kinase C in solid and hematologic malignancies.
about
Intra-lesional injection of the novel PKC activator EBC-46 rapidly ablates tumors in mouse modelsARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC.A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy.Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder.M-CSF induces monocyte survival by activating NF-κB p65 phosphorylation at Ser276 via protein kinase C.Combination treatments with the PKC inhibitor, enzastaurin, enhance the cytotoxicity of the anti-mesothelin immunotoxin, SS1P.Bone marrow microenvironment and the identification of new targets for myeloma therapy.Wealth of opportunity - the C1 domain as a target for drug development.Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signalingProtein kinase C, an elusive therapeutic target?Kinase inhibitors as potential agents in the treatment of multiple myeloma.Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies.AKT as a therapeutic target in multiple myeloma.Phorbol ester phorbol-12-myristate-13-acetate induces epithelial to mesenchymal transition in human prostate cancer ARCaPE cells.Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status.INPP4B suppresses prostate cancer cell invasionTargeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.The serine-threonine kinase p90RSK is a new target of enzastaurin in follicular lymphoma cells.HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells.Novel PKCs activate ERK through PKD1 in MCF-7 cells.Activation of protein kinase C{eta} by type I interferonsSubmaximal inhibition of protein kinase C restores ADP-induced dense granule secretion in platelets in the presence of Ca2+.
P2860
Q21089659-70ACA95A-4ECA-4B60-8060-64C8B0BED287Q30486336-A63A4F86-6394-4B4C-B4F1-C9DA3614CFD0Q33395607-24294940-CE49-438F-AAAA-27767604328AQ33569854-40FE46D1-14C9-4386-9B30-D63D240AABECQ33573983-1613286C-4B3B-4428-99BD-4E163B8D8FB6Q34116925-B5C44DEE-C8C8-47C3-9DA3-3CA563BC1D95Q35018336-39A95607-D597-4E6F-B4E4-194CD7446DFFQ36162703-504F4B43-5B46-4BDA-9FF2-39FF8F04A3E8Q36168226-ECCD19C4-8F63-448A-A4F7-B768FA75E682Q37100742-4AEDD7ED-5CEA-4F30-AF51-42D8B68630D0Q37141320-1BF76F1D-D08B-458A-B8C2-60757E0F2266Q37697253-1B7FD1D9-8DEA-4433-AB67-1E354992BFB9Q37884624-EF50EBD5-1BD1-4202-A151-586E264760A7Q38218256-23F7BBC7-DEC9-4962-A601-9B554E0F1EBBQ38570239-8F820F83-8C38-4A5F-BAB4-36BA9E84FD8DQ38902467-C702B08A-E872-4A2E-BBA3-ACF8826B9880Q38953956-7832F4D5-08FD-4002-BBD4-C9481D105E6DQ38960661-ED4AADDF-DBDE-4C7C-8E01-A23FEAC02A50Q39102576-76A25A0C-AF75-421D-910C-1EF561C98E88Q39525805-8ED3C314-D3BD-482E-B541-7CB9C9CBC37AQ39631841-204718F4-DEA1-405E-9F02-3321F97DE43FQ39884881-91AA35B6-2A67-4CE2-AB72-A4B6A98A5395Q42772012-1D0F432E-C1F3-429A-9A03-67BF92538ED0
P2860
The therapeutic role of targeting protein kinase C in solid and hematologic malignancies.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The therapeutic role of targeting protein kinase C in solid and hematologic malignancies.
@en
type
label
The therapeutic role of targeting protein kinase C in solid and hematologic malignancies.
@en
prefLabel
The therapeutic role of targeting protein kinase C in solid and hematologic malignancies.
@en
P2093
P2860
P1476
The therapeutic role of targeting protein kinase C in solid and hematologic malignancies.
@en
P2093
Dharminder Chauhan
Klaus Podar
Marc S Raab
P2860
P304
P356
10.1517/13543784.16.10.1693
P407
P577
2007-10-01T00:00:00Z